Vir/GSK Move Lead Coronavirus Antibody Into Phase III
Safety In 20 Phase II Patients Enabled Testing In 1,300 People
Executive Summary
Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.
You may also be interested in...
Vir Says Its Best-In-Class COVID-19 Antibody Profile Is Holding Up
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.
Coronavirus Update: Moderna Snags Vaccine EUA
The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.
GSK Venture Capital Arm Goes Independent With $500m Fund
Having been under GSK's umbrella since 1985, SR One is striking out on its own, having closed the largest first-time VC fund this year.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports